GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment

GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, GoodRx Holdings, Inc. (NASDAQ:GDRX) announced launching a new subscription service focused on erectile dysfunction (ED) treatment. The new service aims to innovate access to ED care by addressing common barriers such as high costs, social stigma, long wait times, and inconvenience.

The key features of GoodRx Holdings, Inc.’s (NASDAQ:GDRX) new subscription service include an All-in-One Solution through which customers can book virtual consultations, get access to FDA-approved medicines, and also get discreet home deliveries. The subscription starts as low as $18 per month, with the final cost depending on the prescribed medication. We recognize that many men delay or entirely avoid treatment for ED due to stigma, costs, and the inconvenience of traditional healthcare pathways,” said Katelyn Pelak, VP and Head of Product at GoodRx Holdings, Inc. (NASDAQ:GDRX).

A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy.

Moreover, the company also released its latest study on ED, revealing nearly 1 in 3 men in the United States report difficulties with erections, but fewer than 14% use any treatment, largely due to insurance coverage gaps and social stigma.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading US healthcare company that helps consumers save money on prescription medications by providing free access to drug price comparisons, digital coupons, and discounts at over 70,000 pharmacies nationwide. The company operates through a mobile app and website where users can get medications, access telemedicine services to consult doctors online and receive prescriptions without insurance. It is one of the best small-cap growth stocks to buy according to analysts.

While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.